Duravest, Inc. Announces Additional Appointments to its Medical Advisory Board.

CHICAGO -- Duravest, Inc. (OTC BB:DUVT, XETRA:DUV) is a publicly traded holding company that initiates and develops strategic investments in leading edge medical technologies. Duravest has assembled world-class medical and scientific advisory boards to support the company's unique expertise in cross-disciplinary technology development and to assist its subsidiaries in their clinical trial and market development. Duravest is pleased to announce the appointments of Dr. John Lopez and Dr. Donald Landry to the medical advisory board (MAB). Both bring extensive experience in the development of advanced medical technologies and clinical trials. Last month, the Company announced two initial appointments to its medical advisory board - Dr. Ron Waksman and Dr. Peter Bonis who also have strong experience in clinical trial design, implementation and evaluation.

John Lopez, MD is Associate Professor of Medicine and Director of Cardiac Catheterization and Intervention at the University of Chicago Hospitals. Dr. Lopez has a long standing interest in coronary and peripheral vascular disease, with specific research interests related to novel interventional cardiology approaches to treating these disorders. This includes clinical research interests in novel devices and pharmacologic approaches to interventional procedures, as well as clinical and preclinical studies with angiogenesis and gene therapy for vascular disease, investigational approaches to chronic angina, and clinical research projects related to the use and development of three-dimensional intravascular ultrasound imaging. Dr. Lopez is a Fellow of the American College of Cardiology, a Fellow of the Society of Cardiac Angiography and Intervention and an active member of the American Heart Association Council on Atherosclerosis, Thrombosis, and Vascular Biology. Dr. Lopez received his medical degree from the Columbia University College of Physicians & Surgeons and completed his residency and fellowship training at the Beth Israel Hospital in Boston and Harvard Medical School.

Dr. Ogan Gurel - CEO of Duravest - noted that "Dr. Lopez has a deep background in the development of novel approaches to coronary artery disease both at the preclinical and clinical level. He will be an absolutely invaluable resource for our Estracure subsidiary as it develops its next generation drug-eluting stent. Importantly, Dr. Lopez' broad background - including advanced diagnostic modalities such as three-dimensional intravascular ultrasound - is also of importance in maximizing the full development of our innovative technology portfolio." Dr. Lopez added: "The Estracure technology is a unique approach to drug eluting stents, and potentially represents the future of this field. I am extremely pleased to be a part of the team assisting in the development of this technology.

Don Landry, PhD, MD is Professor of Medicine and Director of the Division of Experimental Therapeutics at the Columbia University College of Physicians & Surgeons. He is also the Director of the Division of Nephrology. His laboratory in Experimental Therapeutics focuses on innovative organic chemical solutions to intractable and unmet medical problems. Dr. Landry obtained a PhD degree in organic chemistry from Harvard University with Nobel laureate Robert Burns Woodward, his MD from the Columbia University College of Physicians & Surgeons and completed residency training at the Massachusetts General Hospital and Harvard Medical School.

Dr. Landry commented that "Duravest has clearly identified an important niche in both emphasizing the growing importance of safety in medical technology development as well as the challenging - yet increasingly important area - of inter-disciplinary technology development. In addition, mechanisms to accelerate medical technology development are urgently needed and the Duravest model holds great potential to help meet that need." Dr. Gurel added that "The appointment of Dr. Landry adds significant expertise to our team. He is a world leader in a number of fields including artificial enzymes and vasodilatory shock and the combination of his academic stature and industry understanding will add tremendously to our ability to support our technology development."

Background on Duravest, Inc.

Duravest, Inc. (OTC BB:DUVT, XETRA:DUV) seeks innovative and safe medical technologies in their preclinical and breakthrough stages and helps move them toward successful commercialization through key strategic partnerships. Duravest has two subsidiaries - Estracure, Inc. and Bio-Magnetic Therapy Systems, Inc. (BMTS). Estracure is currently developing a next-generation coronary stent based on proprietary estrogen-based technologies which minimize restenosis and potentially prevent progression of coronary lesions. The worldwide coronary stent market was valued at $5.1 billion in 2004 and is estimated to grow to $5.8 billion by 2008. Based on the results of a multi-center Phase II "proof-of-concept" trial in humans and ongoing pig trials, Phase II/III trials with the proprietary 17-beta-estradiol, drug, stent and polymer combination are being currently planned for patient accrual later this year. BMTS is a leading German-US medical technology firm dedicated to the safe, non-invasive treatment of orthopedic injuries, osteoarthritis and osteoporosis. Each year it is estimated that 2% of the US population incurs a sports-related injury, while 1% of the US population suffers from a work-related injury. For osteoarthritis, it is estimated that by the year 2020, the number of US residents affected will increase from 41 million to more than 59 million (or 19 % of the population). BMTS' proprietary, patented devices based on the PST(TM) technology are in clinical use in Germany with further expansion being planned for the European, Asian and U.S. markets.

Safe Harbor Forward Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals or assumptions of future events are not statements of historical fact and may be considered forward looking statements. They involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated.